Clinical Adoption Castle Biosciences offers a diverse portfolio of proprietary tests across dermatologic cancers, Barrett’s esophagus, and uveal melanoma, presenting clear opportunities to partner with larger dermatology networks, oncology centers, and pathology labs to accelerate adoption. Focus on cross-selling complementary tests within patient care pathways and establishing payer-supported value propositions to integrate these tests into standard-of-care decision making.

Geographic Expansion With a Texas HQ and multiple laboratories, plus recent expansion activities, there is capacity to scale national coverage and support large health systems. Target regional healthcare networks and academic centers with centralized testing partnerships, faster turnaround, and localized support to drive broader test utilization.

Strategic Partnerships Recent collaboration activity, including SciBase AB, signals openness to co-development and joint studies. Leverage this to pursue additional partnerships with pharma and biotech players in dermatology, GI oncology, and ocular oncology to fund trials, co-market tests, and expand data-driven care pathways.

Market Validation Industry recognition and conference engagement, along with solid early-2026 revenue signals, provide a compelling ROI narrative for payers and providers. Use awards and clinical outcomes data to support value-based contracting and expedite coverage discussions for existing and pipeline tests.

Portfolio Synergy A five-test portfolio aligned along the patient care continuum enables cross-sell and bundling opportunities within hospitals and lab networks. Develop multi-test procurement strategies, bundled pricing, and clinician education to drive broader adoption across dermatology, GI, and ocular oncology teams.